ClinicalTrials.gg
RecruitingNCT07667621Updated Nov 20, 2026

A Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency Department

A Phase 1 interventional study of Rimegepant and Zavegepant in Migraine, Migraine Disease and Migraine in Adults, sponsored by University of South Florida. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by University of South Florida · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Nov 20, 2026Now RecruitingEligibility revised+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies testing rimegepant in Migraine Disorders — 13 open to participants now, 15 under way, 6 of them phase 3. rimegepant · Migraine Disorders.

Planned enrollment
27th of 32
100 · median 618
Started
2026
with 5 others
Phase 1
2 of 32
1 open now
Primary completion
2027-07
later than 5 of 14 live
Registered
28th of 32
by date
Lead sponsor
1 of 32
University of South Florida

Among the 32 studies testing rimegepant in Migraine Disorders, this one is the 27th largest by planned enrollment, is one of 6 that started in 2026, is one of 2 in phase 1, reaches primary completion later than 5 of the 14 other live ones, and was the 28th registered.

Migraine Disorders

1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

13 of the 32 studies testing rimegepant in Migraine Disorders are open now, in 12 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About rimegepant

rimegepant: first FDA approval 2020 (NURTEC ODT), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing rimegepant in Migraine Disorders, or all of them as a file.
02

Study summary

Prospective, single-site, open-label, non-controlled pilot study consisting of two parallel trials. Participants will receive rimegepant or zavegepant for acute migraine treatment during a single Emergency Department visit, with post-discharge follow-up through 28 days. Participants will be allocated to either the rimegepant trial or the zavegepant trial. The study design does not include a placebo or active comparator control group, and the two gepant study drugs are not designed to function as active comparator groups. The objective in this investigation is to examine relief from either rimegepant or zavegepant in separate parallel trials.

03

Conditions studied

  • Migraine
  • Migraine Disease
  • Migraine in Adults
  • Migraine Headache
  • Acute Migraine
  • Migraine Without Aura
  • Migraine With Aura
04

Who can participate

The criteria were revised on the registry on Nov 20, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • At least 18 years of age

      • Capacity to provide (without a Representative)
      • Emergency Department presentation for a headache consistent with migraine, based either on the treating clinical team's judgement, or fulfillment of International Classification of Headache Disorders (ICHD-3) criteria for migraine without aura or with typical aura, or for probable migraine without aura or with typical aura. It is acceptable if current headache duration is >72 hours. Must have been headache free for >48 hours prior to current attack.
      • Willing to participate in post-discharge telephone assessments
      • English and/or Spanish speaking patients

Exclusion criteria

Exclusion Criteria:

    • Use of intranasal decongestants within 1 hour prior to study drug administration, due to the potential to decrease absorption of intranasal zavegepant.

      • Medication-related exclusions applicable to both treatment groups:

Use within 5 half-lives, of a strong or moderate inducer or a strong CYP3A4 inhibitor.

  • Additional exclusions applicable to participants assigned to zavegepant: Use within 5 half-lives, of an OATP1B3 or NTCP transporter inhibitor or inducer.
  • History of ischemic cardiovascular disease, diabetes, or hypertension (diagnosed or likely based on multiple readings), that was recently diagnosed within 3 months of screening or is currently uncontrolled or unstable
  • History of any stroke within 3 months, or any lifetime stroke and age ≥65 years
  • History of significant peripheral vascular disease, as assessed by the investigator or qualified delegate
  • History of Raynaud's Phenomenon (medically diagnosed, or non-medically diagnosed with affirmative responses to both unusual sensitivity and finger color change with cold exposure)
  • History of severe hepatic impairment, as assessed by the investigator or qualified delegate
  • History of kidney disease stage 4 ( \<30 mL/min/1.73 m2)
  • History of reaction to rimegepant, zavegepant, or to any included inactive ingredients
  • Lifetime use of CGRP-targeting acute or preventive migraine medications
  • In custody of law enforcement
  • Current pregnancy or lactation

    • All individuals of must have a negative pregnancy test at screening (urine or serum).
    • A person is considered to be of childbearing potential if possessing female reproductive organs at birth, post-menarchal, has not reached a state (≥12 continuous months of amenorrhea with no cause identified other than menopause), and is not permanently infertile due to surgery (i.e., removal of ovaries, fallopian tubes, and uterus) or another cause as determined by the investigator (e.g., Müllerian agenesis).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Rimegepant (Parallel Trial)

    Participants receive a single oral dose of rimegepant 75 mg orally disintegrating tablet during an Emergency Department visit for the acute treatment of migraine. This arm represents one of two independent, parallel pilot trials evaluating the effectiveness and safety of gepant medications in the Emergency Department. This arm is not intended for comparison with the zavegepant arm.

    Drug: Rimegepant

  • Experimental
    Zavegepant (Parallel Trial)

    Participants receive a single dose of zavegepant 10 mg administered as an intranasal spray during an Emergency Department visit for the acute treatment of migraine. This arm represents one of two independent, parallel pilot trials evaluating the effectiveness and safety of gepant medications in the Emergency Department. This arm is not intended for comparison with the rimegepant arm.

    Drug: Zavegepant

Interventions

  • Rimegepant 75 mg orally disintegrating tablet administered as a single dose during an Emergency Department visit for the acute treatment of migraine. The tablet is placed on or under the tongue and allowed to dissolve without water, consistent with FDA-approved labeling.

  • Zavegepant 10 mg nasal spray administered as a single spray into one nostril during an Emergency Department visit for the acute treatment of migraine. Administration is consistent with FDA-approved labeling

06

What researchers measure

Primary outcomes

  1. Pain relief at 2 hours without rescue medication

    Evaluate the effectiveness of rimegepant 75 mg ODT or zavegepant 10 mg nasal spray as acute migraine treatments administered during ED encounters • Percentage of participants with pain relief of "mild" or "none" on a 4-point scale (none, mild, moderate, severe) at 2 hours post-study drug administration, without rescue medication

    Time frame: 2 hours post-study drug administration

Secondary outcomes

  1. Pain relief at 2 hours (with or without rescue medication)

    Evaluate the effectiveness of rimegepant 75 mg ODT or zavegepant 10 mg nasal spray as acute migraine treatments at 2 hours, with or without rescue medications • Percentage of participants with pain relief achieving "mild" or "none" on a 4-point scale at 2 hours post-study drug administration, analyzed in 2 groups: or 1) achieved pain relief with rimegepant or zavegepant plus rescue medication, or 2) did not achieve pain relief.

    Time frame: 2 hours post-study drug administration

  2. Early pain relief at 60 minutes

    Evaluate the effectiveness of rimegepant 75 mg ODT or zavegepant 10 mg nasal spray as acute migraine treatments at a timepoint earlier than 2 hours • Percentage of participants with pain relief achieving "mild" or "none" on a 4-point scale at 60 minutes post-study drug administration

    Time frame: 60 minutes post-study drug administration

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Jul 2027, 10 months after the start.

Of 53 phase 1 interventional studies under Migraine Disorders, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 19. This study's planned 10 months is above that.

Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Sep 2026, on Oct 27, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2026
First posted
Jun 25, 2026
StartActual
Sep 15, 2026was Jul 2026
Primary completionEst.
Jul 2027
CompletionEst.
Aug 2027
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 27, 2026
Sites
Tampa General Hospital Emergency Room is now Recruiting
Oct 27, 2026
Start date
Jul 2026→Sep 15, 2026 (actual)
Oct 27, 2026
Eligibility
3 exclusion criteria added, 2 removed
What changed in the criteria
Exclusion criteria
  • RemovedUse of analgesics or abortive headache medications within 60 minutes of study medication administration
  • RemovedUse of the following drug/food categories with potential for drug interactions within 7 days or 5 half-lives, whichever is longer: 1) CYP3A strong or moderate inducers, 2) CYP3A4 strong inhibitors, 3) P-glycoprotein (P-gp) inhibitors, 4) OATP1B3 transporter potent inhibitors/inducers, 5) NTCP transporter potent inhibitors/inducers
  • AddedMedication-related exclusions applicable to both treatment groups:
  • AddedUse within 5 half-lives, of a strong or moderate CYP3A inducer or a strong CYP3A4 inhibitor.
  • AddedAdditional exclusions applicable to participants assigned to zavegepant: Use within 5 half-lives, of an OATP1B3 or NTCP transporter inhibitor or inducer.
Nov 20, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Tampa General Hospital Emergency Room · Tampa, United StatesContact s•••@tgh.org · •••7116→h•••@tgh.org · •••7289
Oct 27, 2026
Show all 2 updates
  1. Nov 20, 2026
    Eligibility 3 exclusion criteria added, 2 removed
    What changed in the criteria
    Exclusion criteria
    • RemovedUse of analgesics or abortive headache medications within 60 minutes of study medication administration
    • RemovedUse of the following drug/food categories with potential for drug interactions within 7 days or 5 half-lives, whichever is longer: 1) CYP3A strong or moderate inducers, 2) CYP3A4 strong inhibitors, 3) P-glycoprotein (P-gp) inhibitors, 4) OATP1B3 transporter potent inhibitors/inducers, 5) NTCP transporter potent inhibitors/inducers
    • AddedMedication-related exclusions applicable to both treatment groups:
    • AddedUse within 5 half-lives, of a strong or moderate CYP3A inducer or a strong CYP3A4 inhibitor.
    • AddedAdditional exclusions applicable to participants assigned to zavegepant: Use within 5 half-lives, of an OATP1B3 or NTCP transporter inhibitor or inducer.
  2. Oct 27, 2026
    Not yet recruiting→Recruiting
    Tampa General Hospital Emergency Room is now Recruiting
    Start date Jul 2026→Sep 15, 2026 (now actual)
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Tampa General Hospital Emergency Room · Tampa, United StatesContact s•••@tgh.org · •••7116→h•••@tgh.org · •••7289
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07667621
Collaborators
Pfizer, Tampa General Hospital
Responsible party
Roland Merchant (Vice Chair of Research and Assistant Dean of Faculty Development, USF Health, University of South Florida) — Principal investigator
First posted
Jun 25, 2026
Start date
Sep 15, 2026
Primary completion
Jul 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Nov 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rimegepant · Zavegepant

Start the discussion